Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. (Q37523202)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

review article

1 reference

title

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

Erb-b2 receptor tyrosine kinase 2

31 January 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

author name string

José Baselga

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

English

0 references

publication date

18 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

463-475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19536107 AND SRC:MED&resulttype=core&format=json

ERBB receptors and cancer: the complexity of targeted inhibitors

31 January 2020

cites work

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

31 March 2020

1 reference

Untangling the ErbB signalling network

31 March 2020

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

31 March 2020

1 reference

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

31 March 2020

1 reference

Structure of the extracellular region of HER3 reveals an interdomain tether

31 March 2020

1 reference

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

31 March 2020

1 reference

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

31 March 2020

1 reference

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

31 March 2020

1 reference

Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

31 March 2020

1 reference

EGF Receptor Activation: Push Comes to Shove

31 March 2020

1 reference

Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein

31 March 2020

1 reference

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

31 March 2020

1 reference

ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface

31 March 2020

1 reference

The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation

31 March 2020

1 reference

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

31 March 2020

1 reference

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

31 March 2020

1 reference

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

31 March 2020

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

31 March 2020

1 reference

HER-2 testing in breast cancer using parallel tissue-based methods

31 March 2020

1 reference

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers

31 March 2020

1 reference

Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma

31 March 2020

1 reference

Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland

31 March 2020

1 reference

FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene

31 March 2020

1 reference

HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.

31 March 2020

1 reference

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer

31 March 2020

1 reference

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

31 March 2020

1 reference

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

31 March 2020

1 reference

The phosphoinositide 3-kinase pathway

31 March 2020

1 reference

ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

31 March 2020

1 reference

ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.

31 March 2020

1 reference

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

31 March 2020

1 reference

c-erbB-3 protein expression in ductal carcinoma in situ of the breast

31 March 2020

1 reference

c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival

31 March 2020

1 reference

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.

31 March 2020

1 reference

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

31 March 2020

1 reference

Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer

31 March 2020

1 reference

c-erbB3 protein expression in ovarian cancer

31 March 2020

1 reference

ErbB-3 predicts survival in ovarian cancer.

31 March 2020

1 reference

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

31 March 2020

1 reference

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

31 March 2020

1 reference

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

31 March 2020

1 reference

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

31 March 2020

1 reference

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

31 March 2020

1 reference

Insights from transgenic mouse models of ERBB2-induced breast cancer

31 March 2020

1 reference

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

31 March 2020

1 reference

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

31 March 2020

1 reference

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

31 March 2020

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

31 March 2020

1 reference

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

31 March 2020

1 reference

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

31 March 2020

1 reference

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

31 March 2020

1 reference

Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.

31 March 2020

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.

31 March 2020

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

31 March 2020

1 reference

A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions

31 March 2020

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

31 March 2020

1 reference

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

31 March 2020

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

31 March 2020

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

31 March 2020

1 reference

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

31 March 2020

1 reference

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

31 March 2020

1 reference

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety

31 March 2020

1 reference

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

EGF receptor inhibition: Attacks on multiple fronts

31 March 2020

1 reference

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

31 March 2020

1 reference

Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.

31 March 2020

1 reference

Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.

31 March 2020

1 reference

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

31 March 2020

1 reference

A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization

31 March 2020

1 reference

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

31 March 2020

1 reference

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

31 March 2020

1 reference

Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway

31 March 2020

1 reference

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

31 March 2020

1 reference

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

31 March 2020

1 reference

A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies

31 March 2020

1 reference

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

31 March 2020

1 reference

erbB2 is required for G protein-coupled receptor signaling in the heart

31 March 2020

1 reference

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

31 March 2020

1 reference

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

31 March 2020

1 reference

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

31 March 2020

1 reference

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

31 March 2020

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

31 March 2020

1 reference

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

31 March 2020

1 reference

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

31 March 2020

1 reference

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

31 March 2020

1 reference

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

31 March 2020

1 reference

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

31 March 2020

1 reference

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

31 March 2020

1 reference

31 March 2020

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

31 March 2020

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

31 March 2020

1 reference

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

31 March 2020

1 reference

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

PI3K pathway alterations in cancer: variations on a theme

31 March 2020

1 reference

31 March 2020

Phosphoinositide kinases

1 reference

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

31 March 2020

1 reference

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer

31 March 2020

1 reference

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

31 March 2020

1 reference

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

31 March 2020

1 reference

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

31 March 2020

1 reference

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

31 March 2020

1 reference

12 December 2020

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

1 reference

12 December 2020

Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

1 reference

12 December 2020

Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

1 reference

12 December 2020

Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.

1 reference

12 December 2020

Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin

1 reference

12 December 2020

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

1 reference

12 December 2020

The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.

1 reference

12 December 2020

Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo

1 reference

12 December 2020

Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera

1 reference

12 December 2020

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

1 reference

12 December 2020

NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice

1 reference

12 December 2020

Characteristics of EGFR family-mediated HRG signals in human ovarian cancer

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020

The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast

1 reference

12 December 2020